General MedicationsFILM COATEDGeneric
BOSUTINIB
BOSUTINIB MONOHYDRATE
Standard Dose
400MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: None (Tentative Approval)
Summary
Approval overview BOSUTINIB is listed in Drugs@FDA under application 209624 (ANDA).
Review priority: STANDARD Marketing status: None (Tentative Approval) Active ingredient BOSUTINIB MONOHYDRATE Form and strength TABLET;FILM COATED - 400MG Sponsor MSN LABORATORIES PRIVATE LTD Submission history Latest submission status date: 2025-05-28 00:00:00.
Structured Monograph
Clinical summary
Approval overview BOSUTINIB is listed in Drugs@FDA under application 209624 (ANDA). Review priority: STANDARD Marketing status: None (Tentative Approval) Active ingredient BOSUTINIB MONOHYDRATE Form and strength TABLET;FILM COATED - 400MG Sponsor MSN LABORATORIES PRIVATE LTD Submission history Latest submission status date: 2025-05-28 00:00:00. Submission type: ORIG.
Monitoring
- • Marketing status: None (Tentative Approval)
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.